Do analysts recommend CTOR or AIMD?

Citius Oncology presently has a consensus target price of $6.00, indicating a potential upside of 823.08%. Given Citius Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Citius Oncology is more favorable than Ainos. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Oncology 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CTOR or AIMD more profitable?

Citius Oncology has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Citius Oncology's return on equity of -99.47% beat Ainos' return on equity. Company Net Margins Return on Equity Return on Assets Citius Oncology N/A -99.47% -42.16% Ainos -11,912.10% -160.55% -62.29%

Do analysts prefer UPXI or AIMD?

Upexi presently has a consensus target price of $8.10, suggesting a potential upside of 867.51%. Given Upexi's stronger consensus rating and higher possible upside, equities research analysts plainly believe Upexi is more favorable than Ainos. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Upexi 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, UPXI or AIMD?

Upexi has higher revenue and earnings than Ainos. Upexi is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Upexi $15.81M 4.17 -$13.68M -$0.62 N/A Ainos $120K 134.90 -$14.77M -$2.89 N/A

Is UPXI or AIMD more profitable?

Upexi has a net margin of -874.00% compared to Ainos' net margin of -11,912.10%. Upexi's return on equity of -66.70% beat Ainos' return on equity. Company Net Margins Return on Equity Return on Assets Upexi -874.00% -66.70% -19.56% Ainos -11,912.10% -160.55% -62.29%

Do analysts prefer PMVP or AIMD?

PMV Pharmaceuticals currently has a consensus price target of $4.00, suggesting a potential upside of 181.69%. Given PMV Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe PMV Pharmaceuticals is more favorable than Ainos. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PMV Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75 Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PMVP or AIMD more profitable?

PMV Pharmaceuticals has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. PMV Pharmaceuticals' return on equity of -68.98% beat Ainos' return on equity. Company Net Margins Return on Equity Return on Assets PMV Pharmaceuticals N/A -68.98% -62.70% Ainos -11,912.10% -160.55% -62.29%

Do analysts rate AIMD or IMMP?

Prima BioMed has a consensus price target of $5.50, suggesting a potential upside of 1,170.79%. Given Prima BioMed's stronger consensus rating and higher possible upside, analysts clearly believe Prima BioMed is more favorable than Ainos. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Prima BioMed 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, AIMD or IMMP?

Ainos has higher earnings, but lower revenue than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ainos $120K 134.90 -$14.77M -$2.89 N/A Prima BioMed $6.69M 9.53 -$39.78M N/A N/A

Is AIMD or IMMP more profitable?

Prima BioMed has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Prima BioMed's return on equity of 0.00% beat Ainos' return on equity. Company Net Margins Return on Equity Return on Assets Ainos -11,912.10% -160.55% -62.29% Prima BioMed N/A N/A N/A

Do analysts prefer FLNA or AIMD?

Cassava Sciences currently has a consensus price target of $5.00, suggesting a potential upside of 358.72%. Given Cassava Sciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Cassava Sciences is more favorable than Ainos. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cassava Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is FLNA or AIMD more profitable?

Cassava Sciences has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Cassava Sciences' return on equity of -53.90% beat Ainos' return on equity. Company Net Margins Return on Equity Return on Assets Cassava Sciences N/A -53.90% -34.20% Ainos -11,912.10% -160.55% -62.29%

Ainos (AIMD) Competitors

$1.90 0.00 (0.00%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$1.89 -0.01 (-0.47%)

As of 07:52 AM Eastern

Compare

AIMD vs. CTOR, UPXI, PMVP, IMMP, and FLNA

Should you buy Ainos stock or one of its competitors? MarketBeat compares Ainos with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ainos include Citius Oncology (CTOR), Upexi (UPXI), PMV Pharmaceuticals (PMVP), Prima BioMed (IMMP), and Cassava Sciences (FLNA). These companies are all part of the "pharmaceutical products" industry.

How does Ainos compare to Citius Oncology?

Citius Oncology (NASDAQ:CTOR) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Ainos has higher revenue and earnings than Citius Oncology. Citius Oncology is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A
Ainos	$120K	134.90	-$14.77M	-$2.89	N/A

In the previous week, Citius Oncology and Citius Oncology both had 1 articles in the media. Ainos' average media sentiment score of 1.89 beat Citius Oncology's score of 1.87 indicating that Ainos is being referred to more favorably in the news media.

Company	Overall Sentiment
Citius Oncology	Very Positive
Ainos	Very Positive

70.5% of Citius Oncology shares are owned by institutional investors. 9.8% of Citius Oncology shares are owned by company insiders. Comparatively, 9.8% of Ainos shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Citius Oncology has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Citius Oncology's return on equity of -99.47% beat Ainos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-99.47%	-42.16%
Ainos	-11,912.10%	-160.55%	-62.29%

Citius Oncology presently has a consensus target price of $6.00, indicating a potential upside of 823.08%. Given Citius Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Citius Oncology is more favorable than Ainos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Citius Oncology has a beta of 3.47, suggesting that its stock price is 247% more volatile than the broader market. Comparatively, Ainos has a beta of 2.43, suggesting that its stock price is 143% more volatile than the broader market.

Summary

Citius Oncology beats Ainos on 10 of the 14 factors compared between the two stocks.

How does Ainos compare to Upexi?

Upexi (NASDAQ:UPXI) and Ainos (NASDAQ:AIMD) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Upexi has a net margin of -874.00% compared to Ainos' net margin of -11,912.10%. Upexi's return on equity of -66.70% beat Ainos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upexi	-874.00%	-66.70%	-19.56%
Ainos	-11,912.10%	-160.55%	-62.29%

5.7% of Upexi shares are owned by institutional investors. 9.0% of Upexi shares are owned by company insiders. Comparatively, 9.8% of Ainos shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Upexi has a beta of -0.29, indicating that its stock price is 129% less volatile than the broader market. Comparatively, Ainos has a beta of 2.43, indicating that its stock price is 143% more volatile than the broader market.

Upexi has higher revenue and earnings than Ainos. Upexi is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upexi	$15.81M	4.17	-$13.68M	-$0.62	N/A
Ainos	$120K	134.90	-$14.77M	-$2.89	N/A

In the previous week, Upexi and Upexi both had 1 articles in the media. Ainos' average media sentiment score of 1.89 beat Upexi's score of 0.93 indicating that Ainos is being referred to more favorably in the news media.

Company	Overall Sentiment
Upexi	Positive
Ainos	Very Positive

Upexi presently has a consensus target price of $8.10, suggesting a potential upside of 867.51%. Given Upexi's stronger consensus rating and higher possible upside, equities research analysts plainly believe Upexi is more favorable than Ainos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upexi	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Upexi beats Ainos on 10 of the 15 factors compared between the two stocks.

How does Ainos compare to PMV Pharmaceuticals?

PMV Pharmaceuticals (NASDAQ:PMVP) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

PMV Pharmaceuticals has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. PMV Pharmaceuticals' return on equity of -68.98% beat Ainos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PMV Pharmaceuticals	N/A	-68.98%	-62.70%
Ainos	-11,912.10%	-160.55%	-62.29%

PMV Pharmaceuticals currently has a consensus price target of $4.00, suggesting a potential upside of 181.69%. Given PMV Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe PMV Pharmaceuticals is more favorable than Ainos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, PMV Pharmaceuticals had 2 more articles in the media than Ainos. MarketBeat recorded 3 mentions for PMV Pharmaceuticals and 1 mentions for Ainos. Ainos' average media sentiment score of 1.89 beat PMV Pharmaceuticals' score of 0.72 indicating that Ainos is being referred to more favorably in the news media.

Company	Overall Sentiment
PMV Pharmaceuticals	Positive
Ainos	Very Positive

90.2% of PMV Pharmaceuticals shares are held by institutional investors. 10.2% of PMV Pharmaceuticals shares are held by insiders. Comparatively, 9.8% of Ainos shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

PMV Pharmaceuticals has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market. Comparatively, Ainos has a beta of 2.43, indicating that its share price is 143% more volatile than the broader market.

Ainos has higher revenue and earnings than PMV Pharmaceuticals. PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.49	N/A
Ainos	$120K	134.90	-$14.77M	-$2.89	N/A

Summary

PMV Pharmaceuticals beats Ainos on 10 of the 16 factors compared between the two stocks.

How does Ainos compare to Prima BioMed?

Ainos (NASDAQ:AIMD) and Prima BioMed (NASDAQ:IMMP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

Prima BioMed has a consensus price target of $5.50, suggesting a potential upside of 1,170.79%. Given Prima BioMed's stronger consensus rating and higher possible upside, analysts clearly believe Prima BioMed is more favorable than Ainos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Ainos has higher earnings, but lower revenue than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$120K	134.90	-$14.77M	-$2.89	N/A
Prima BioMed	$6.69M	9.53	-$39.78M	N/A	N/A

Prima BioMed has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Prima BioMed's return on equity of 0.00% beat Ainos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ainos	-11,912.10%	-160.55%	-62.29%
Prima BioMed	N/A	N/A	N/A

Ainos has a beta of 2.43, meaning that its share price is 143% more volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.23, meaning that its share price is 123% more volatile than the broader market.

2.3% of Prima BioMed shares are held by institutional investors. 9.8% of Ainos shares are held by insiders. Comparatively, 3.1% of Prima BioMed shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Prima BioMed had 1 more articles in the media than Ainos. MarketBeat recorded 2 mentions for Prima BioMed and 1 mentions for Ainos. Ainos' average media sentiment score of 1.89 beat Prima BioMed's score of 0.94 indicating that Ainos is being referred to more favorably in the media.

Company	Overall Sentiment
Ainos	Very Positive
Prima BioMed	Positive

Summary

Prima BioMed beats Ainos on 9 of the 14 factors compared between the two stocks.

How does Ainos compare to Cassava Sciences?

Cassava Sciences (NASDAQ:FLNA) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations.

38.1% of Cassava Sciences shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by company insiders. Comparatively, 9.8% of Ainos shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Cassava Sciences has a beta of -0.73, indicating that its stock price is 173% less volatile than the broader market. Comparatively, Ainos has a beta of 2.43, indicating that its stock price is 143% more volatile than the broader market.

Cassava Sciences has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Cassava Sciences' return on equity of -53.90% beat Ainos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-53.90%	-34.20%
Ainos	-11,912.10%	-160.55%	-62.29%

In the previous week, Cassava Sciences and Cassava Sciences both had 1 articles in the media. Ainos' average media sentiment score of 1.89 beat Cassava Sciences' score of 1.87 indicating that Ainos is being referred to more favorably in the news media.

Company	Overall Sentiment
Cassava Sciences	Very Positive
Ainos	Very Positive

Cassava Sciences currently has a consensus price target of $5.00, suggesting a potential upside of 358.72%. Given Cassava Sciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Cassava Sciences is more favorable than Ainos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Ainos has higher revenue and earnings than Cassava Sciences. Cassava Sciences is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A
Ainos	$120K	134.90	-$14.77M	-$2.89	N/A

Summary

Cassava Sciences beats Ainos on 8 of the 14 factors compared between the two stocks.

Get Ainos News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AIMD vs. The Competition

Export

Metric	Ainos	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$16.20M	$3.02B	$6.86B	$12.44B
Dividend Yield	N/A	2.08%	2.68%	8.42%
P/E Ratio	-0.66	18.77	26.94	24.38
Price / Sales	134.90	344.35	521.23	91.92
Price / Cash	N/A	56.83	48.59	59.36
Price / Book	1.47	4.20	10.89	6.33
Net Income	-$14.77M	$65.13M	$3.59B	$331.02M
7 Day Performance	3.83%	-2.63%	-1.53%	-0.33%
1 Month Performance	3.26%	2.14%	2.72%	-1.29%
1 Year Performance	-33.57%	23.26%	28.47%	21.30%

Ainos Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AIMD Ainos	1.0828 of 5 stars	$1.90 flat	N/A	-34.0%	$16.20M	$120K	N/A	40	Positive News Gap Up
CTOR Citius Oncology	2.6884 of 5 stars	$0.70 -0.2%	$6.00 +753.5%	-66.5%	$65.37M	N/A	N/A	N/A	Positive News
UPXI Upexi	2.569 of 5 stars	$0.91 +2.0%	$8.10 +787.2%	-86.0%	$65.34M	$15.81M	N/A	130
PMVP PMV Pharmaceuticals	3.008 of 5 stars	$1.23 -1.2%	$5.00 +308.2%	+5.2%	$65.33M	N/A	N/A	50
IMMP Prima BioMed	2.5694 of 5 stars	$0.44 +1.0%	$5.50 +1,164.4%	-74.4%	$63.96M	$4.08M	N/A	2,021

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AIMD) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ainos (AIMD) Competitors

AIMD vs. CTOR, UPXI, PMVP, IMMP, and FLNA

How does Ainos compare to Citius Oncology?

Summary

How does Ainos compare to Upexi?

Summary

How does Ainos compare to PMV Pharmaceuticals?

Summary

How does Ainos compare to Prima BioMed?

Summary

How does Ainos compare to Cassava Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIMD vs. The Competition

Ainos Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ainos (AIMD) Competitors

AIMD vs. CTOR, UPXI, PMVP, IMMP, and FLNA

How does Ainos compare to Citius Oncology?

Which has better valuation and earnings, CTOR or AIMD?

Does the media prefer CTOR or AIMD?

Do institutionals and insiders believe in CTOR or AIMD?

Is CTOR or AIMD more profitable?

Do analysts recommend CTOR or AIMD?

Which has more volatility & risk, CTOR or AIMD?

Summary

How does Ainos compare to Upexi?

Is UPXI or AIMD more profitable?

Do insiders and institutionals have more ownership in UPXI or AIMD?

Which has more volatility & risk, UPXI or AIMD?

Which has better valuation and earnings, UPXI or AIMD?

Does the media prefer UPXI or AIMD?

Do analysts prefer UPXI or AIMD?

Summary

How does Ainos compare to PMV Pharmaceuticals?

Is PMVP or AIMD more profitable?

Do analysts prefer PMVP or AIMD?

Does the media prefer PMVP or AIMD?

Do institutionals & insiders have more ownership in PMVP or AIMD?

Which has more risk and volatility, PMVP or AIMD?

Which has higher earnings & valuation, PMVP or AIMD?

Summary

How does Ainos compare to Prima BioMed?

Do analysts rate AIMD or IMMP?

Which has preferable earnings & valuation, AIMD or IMMP?

Is AIMD or IMMP more profitable?

Which has more risk and volatility, AIMD or IMMP?

Do insiders & institutionals hold more shares of AIMD or IMMP?

Does the media prefer AIMD or IMMP?

Summary

How does Ainos compare to Cassava Sciences?

Do insiders and institutionals hold more shares of FLNA or AIMD?

Which has more risk and volatility, FLNA or AIMD?

Is FLNA or AIMD more profitable?

Does the media refer more to FLNA or AIMD?

Do analysts prefer FLNA or AIMD?

Which has preferable earnings and valuation, FLNA or AIMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIMD vs. The Competition

Ainos Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools